Texas Oncology - Gulf Coast

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Bladder cancer2 trials
• Colorectal cancer2 trials
• Cervical cancer1 trial
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial
• and 1 more

Phase

• Phase 1/23 trials
• Phase 33 trials
• Phase 2/31 trial

Status

• Recruiting7 trials

Lead sponsor

• Pfizer6 trials
• Daiichi Sankyo1 trial

Running trials

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Pfizer· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

  NCT07226999· Phase 2/3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Daiichi Sankyo· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Bladder cancer2 recruiting
• Colorectal cancer2 recruiting
• Cervical cancer1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting